Diamond Hill Capital Comments on Teva Pharmaceutical Industries Ltd

Author's Avatar
Jun 26, 2014

Generic drug manufacturer Teva Pharmaceutical Industries Ltd. (TEVA) benefitted from the addition of a well-respected CEO and the continued successful transition of patients to a new, patent-protected version of the company’s multiple sclerosis drug.

From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.